homogeneous distribution of the active ingredients.

14. The powder formulation according to claim 12 or 13, wherein said first portion of said micronized particles of a physiologically acceptable excipient is 40% to 60%, based on the total weight of all of said micronized particles of a physiologically acceptable excipient.

15. The powder formulation according to any one of claims 12 to 14, whereby the extrafine particle fraction of beclometasone dipropionate, and formoterol fumarate dihydrate is comprised between 20 and 35%, and the extrafine particle fraction of glycopyrronium bromide is comprised between 20 and 30%.

16. The powder formulation according to any one of claims 12 or 15, wherein the physiologically acceptable excipient is alpha-lactose monohydrate.

17. The powder formulation according to any one of claims 12 to 16, wherein the coarse particles have a mass diameter comprised between 210 and 360 μm.

18. A dry powder inhaler device filled with the dry powder formulation of any one of claims 12 to 17.

19. The dry powder formulation of any one of claims 12 to 17 for use for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

20. The dry powder formulation of claim 19, wherein the disease is asthma or chronic obstructive pulmonary disease (COPD).

21. Use of the dry powder formulation of any one of claims 12 to 17 in the manufacture of a medicament for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

22. The use according to claim 21, wherein the disease is asthma or chronic obstructive pulmonary disease (COPD).